Journal
BRITISH JOURNAL OF CANCER
Volume 100, Issue 1, Pages 1-7Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604767
Keywords
angiogenesis; vascular endothelial growth factor; angiogenesis inhibitors; ovarian neoplasms; biomarkers; adverse effects
Categories
Funding
- Medical Research Council [G0601746, G0902173] Funding Source: Medline
- Medical Research Council [G0601746] Funding Source: researchfish
- MRC [G0601746] Funding Source: UKRI
Ask authors/readers for more resources
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
